am 251 has been researched along with Nerve Degeneration in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grabiec, U | 1 |
| Koch, M | 1 |
| Kallendrusch, S | 1 |
| Kraft, R | 1 |
| Hill, K | 1 |
| Merkwitz, C | 1 |
| Ghadban, C | 1 |
| Lutz, B | 1 |
| Straiker, A | 1 |
| Dehghani, F | 1 |
1 other study available for am 251 and Nerve Degeneration
| Article | Year |
|---|---|
The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)).
Topics: Animals; Arachidonic Acids; Cells, Cultured; Dopamine; Excitatory Postsynaptic Potentials; Hippocamp | 2012 |